The two-week clinical trial conducted by DiSilvestro, et al, and published in Phytotherapy Research consisted of 45 subjects suffering from heartburn on average of 3-8 times per week. All subjects were randomly allocated to a FenuLife group, (500 mg per capsule, four capsules taken twice daily), placebo group (four starch capsules taken twice daily) or an over-the-counter (OTC) control group (ranitidine, 75 mg, twice daily). At the end of the trial, results were compared to baseline and showed significant, similar effects for FenuLife fenugreek fiber and the OTC antacid control group.
FenuLife is shown to simultaneously reduce both frequency and severity of acid reflux and heartburn. It is a naturally sourced, unique galactomannan ingredient manufactured from deodorized fenugreek and containing more than 75% soluble fiber. For further information: www.frutarom.com